Pentraxin 3 and atherosclerosis among type 2 diabetic patients

• Published in: Open life sciences 2017-04, Vol.12 (1), p.92-98
• Main Authors: Nabrdalik, Katarzyna, Chodkowski, Artur, Bartman, Wojciech, Tomasik, Andrzej, Kwiendacz, Hanna, Sawczyn, Tomasz, Kukla, Michał, Grzeszczak, Władysław, Gumprecht, Janusz
• Format: Article
• Language: English
• Subjects: atherosclerosis; cardiac function; carotid arteries; diabetes mellitus type 2; intracranial arteries; macrovascular complications; pentraxin 3
• ISSN: 2391-5412; 2391-5412
• DOI: 10.1515/biol-2017-0010

Type 2 diabetes is contemporarily a major social and epidemiological problem and among others is a strong risk factor for cardiovascular diseases. Pentraxin 3, a potential early biomarker of atherosclerosis, is an acute-phase reactant produced by the peripheral tissues where the inflammation takes place. In this study we examined a group of patients with type 2 diabetes with and without cardiovascular complications compared to persons with normal glucose tolerance (patients with cardiovascular complications and healthy volunteers). Plasma pentraxin 3 concentration as well as some basic biochemical blood analysis were performed. Moreover, transcranial and carotid Doppler ultrasound examination as well as transthoracic echocardiography were performed. It turned out that there was an association of plasma pentraxin 3 concentration and carotid atherosclerosis found in the control group of patients with cardiovascular complications but with normal glucose tolerance. In the group of patients with type 2 diabetes and cardiovascular complications we have found an association of plasma pentraxin 3 concentration with diastolic left ventricular dysfunction. Additionally, in the group of patients with type 2 diabetes without cardiovascular disease plasma pentraxin 3 concentration was associated with elevated urinary albumin creatinine ratio. Further studies, on a larger group of patients, are required to confirm these observations.